Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation

Phase 1TerminatedNCT00597441

Sumitomo Pharma Switzerland GmbH6 enrolled

Overview

The objective of this trial is to assess the toxicity of thymus transplantation following unrelated umbilical cord blood transplantation. Emphasis will be placed on adverse events that are not typically associated with umbilical cord blood transplantation. Also, to determine whether engraftment of a third party thymus allograft is feasible in patients who have undergone unrelated umbilical cord blood transplantation. Thymic engraftment will be determined by biopsy of the thymus allograft and immunohistochemical evidence of thymopoiesis. In addition, we would like to assess thymic function by measuring the number of naive T cells and the number of T cell receptor rearrangement excision circles (TRECS), and by assessing the diversity of the T cell receptor beta chain. These data will be compared to age, stem-cell donor source and disease matched historical controls whose stem cell transplants were not followed by a thymus transplant. This will be done in descriptive fashion. Other immune parameters will be followed including T, B, and NK cell numbers, T cell responses to mitogens, antigens, and immunoglobulin production.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Stem Cell Transplantation

Interventions

Thymic Transplantation for Recipients of UCB transplantBIOLOGICAL

Subjects with hematologic malignancies or bone marrow failure disorders will undergo umbilical cord blood transplantation and two months post transplant will have thymic tissue from a third party donor transplanted into the thigh muscle.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects who received a dual cord blood transplant are eligible and must have achieved donor cord blood chimerism of \> 75% in both T-cell and myeloid lineages * At the time of thymus transplantation, subjects cannot have active grade II-IV acute graft versus host disease. * At the time of thymus transplantation, the subject must have an absolute neutrophil count of \> 500/ul and a platelet count of 50,000/ul (even if achieved via transfusion). * At the time of thymus transplantation, the subject must have \< or equal to 50 circulating CD 34+ cells/ul (as measured within 3 weeks of transplant date). * At the time of thymus transplantation, subjects cannot be on greater than 2 mg/kg/day methylprednisolone or its equivalent of steroids. * At the time of thymus transplantation, PT and PTT must be less that 1.5 times the ULN or must be correctable to this level. * At the time of thymus transplantation, subjects cannot require oxygen or have pulmonary disease that would be thought to make general anesthesia a high risk. * Subjects must be between the ages of 18 and 60 years of age. Exclusion Criteria: * Subjects cannot have bone marrow flow cytometry demonstrating residual leukemia * Subjects cannot have insufficient subcutaneous tissue and muscle mass to be able to accept and heal a thymus transplant, as assessed by a surgeon. * Prior to thymus transplantation, subjects cannot have evidence of active disease with HHV6, West Nile Virus, EBV, and CMV.

Locations (1)

Duke University Health System

Durham, North Carolina, United States

Outcomes

Primary Outcomes

Toxicity of thymus transplantation following unrelated umbilical cord blood transplantation. Emphasis will be placed on adverse events that are not typically associated with umbilical cord blood transplantation.

Time frame: 5 years

Secondary Outcomes

To determine whether engraftment of a third party thymus allograft is feasible in patients who have undergone unrelated UCBT. Thymic engraftment will be determined by biopsy of the thymus allograft and immunohistochemical evidence of thymopoiesis.

Time frame: 5 years

To assess thymic function by measuring the number of naive T cells and the number of T cell receptor rearrangement excision circles (TRECS), and by assessing the diversity of the T cell receptor beta chain.

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.